MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility

The p53 tumor suppressor directs the cellular response to many mechanistically distinct DNA-damaging agents and is selected against during the pathogenesis of therapy-related acute myeloid leukemia (t-AML). We hypothesized that constitutional genetic variation in the p53 pathway would affect t-AML r...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ellis, Nathan A., Huo, Dezheng, Yildiz, Ozlem, Worrillow, Lisa J., Banerjee, Mekhala, Le Beau, Michelle M., Larson, Richard A., Allan, James M., Onel, Kenan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2008
Pynciau:
Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2481552/
https://ncbi.nlm.nih.gov/pubmed/18426989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-11-126508
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg